This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with Brent Bellows, a partner with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia, who has a Ph.D. from the University of Alabama at Birmingham in human genetics. Brent traces his path from graduate research in medical genetics and tumor-associated antigens to patent law, including his time at King & Spalding, a clerkship in the Northern District of Georgia, and his work today at KIPS on patent prosecution, portfolio strategy, litigation support, licensing, and expert witness matters. The conversation highlights how Brent’s scientific training and litigation-facing experience inform the way he drafts and prosecutes life sciences patents, with a clear focus on how those assets may ultimately perform in district court, ANDA litigation, and biosimilar disputes.

Gene and Brent discuss what judges actually care about in patent cases, including why the story told in the patent application matters, why consistency from prosecution through litigation can be strategically important, and why some issues that loom large for prosecutors may carry less practical weight in court. Brent explains that district court judges often approach inequitable conduct allegations skeptically unless the conduct is truly egregious, and he offers insight into Markman practice, claim construction, and how life sciences disputes differ from many high-tech cases because the science often dictates the shape and value of the patent claims.

The conversation then moves into the policy and business realities of pharmaceutical innovation, which dominate more than half of the conversation. Brent discusses a variety of issues including Hatch-Waxman, Orange Book listings, paragraph IV certifications, skinny labels, generic entry, clinical trial costs, regulatory exclusivity, and the enormous financial risk associated with bringing new drugs to market. Gene and Brent explore the tension between public demand for lower drug prices and the need for durable incentives that make high-risk drug development economically viable, particularly for oncology, Alzheimer’s, Parkinson’s, antibiotic resistant bacteria, and other difficult-to-treat conditions. The episode closes with a broader innovation-policy message: patents are not a peripheral feature of drug development—they are a core operating asset that enables private-sector investment, supports breakthrough therapies, and ultimately drives the availability of future generic medicines.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.